The Motley Fool

Interested in the Novacyt share price? Read this first!

Image source: Getty Images

The Novacyt (LSE:NYCT) share price really started getting traction back in the early part of 2020. It means a £12,500 investment in the Anglo-French pharma group at the turn of the year would today be worth £773,125.

If you got in early, it’s probably been one of the best performers of your investing life.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

Where it started

Don’t beat yourself up too much if you missed out. In January 2020 there was little market excitement around Novacyt.

It certainly didn’t have multi-million pound recurring contracts with almost every government on the planet. It was just one of those small UK-listed pharma companies struggling to make its voice heard.

It hadn’t reported a profit in any of the previous five years. It had a market value of less than £10m (that’s up to £550m today).

At the time, its molecular diagnostics division, Primerdesign Ltd, was reporting contracts for identifying shellfish health in the French food supply chain. That’s not the kind of thing that gets investors hot under the collar.

Novacyt share price goes boom

On 31 January everything changed. When the Covid outbreak happened, Novacyt spotted its chance. Primerdesign used its molecular testing expertise to design and launch a new test for the novel coronavirus.

The orders started flying in by the tens of thousands. Then the hundreds of thousands. Primerdesign’s coronavirus test won a CE-Mark, the safety standard for health products in the European Economic Area.

No wonder that by the end of February CEO Graham Mullins was “extremely pleased with the commercial interest shown in our test to date“.

And as Primerdesign turned this interest into huge sales, the Novacyt share price rocketed. India, Argentina, the Philippines, and the coveted US market all fell into line.

Is Novacyt a buy in 2020?

Investors like me see the Novacyt share price having risen over 6,185% and are likely to jump to one conclusion. That prices have already risen so much, there’s little value left in me buying in now.

But what do the financials show?

Company accounts for the first half of 2020 show a company now with a very healthy €46m profit. That’s compared to a €1.2m loss for the first half of 2019. Revenue surged tenfold over the same period, from €7.2m to €72.4m.

Primerdesign has rapidly expanded the suite of products available to businesses and governments to include PCR two-gene target tests for Covid-19, trademarked exsig Covid-19 direct testing kits and many more.

And Graham Mullins has told the market that its “transformational” revenues will continue long into 2021.

So what now?

For those of you still reading, the question you want answered is where there’s still value in the Novacyt share price today? I’d say yes. Just because a share has risen a lot doesn’t mean it can’t continue. And especially so with all its extra product lines on offer.

Just look at Astrazeneca. Between the start of 1995 and the end of 1996, the FTSE 100 multinational saw its share price rise nearly 100% from 850p to 1,607p. But if I’d sold then, I would have missed out on another 425% gain to today’s 8,440p price.

If you’re generally more risk-averse and you favour FTSE 100 dividend payers, this might not be the share for you. But fancy a medium-term punt? I’d go for it.

The high-calibre small-cap stock flying under the City’s radar

Adventurous investors like you won’t want to miss out on what could be a truly astonishing opportunity…

You see, over the past three years, this AIM-listed company has been quietly powering ahead… rewarding its shareholders with generous share price growth thanks to a carefully orchestrated ‘buy and build’ strategy.

And with a first-class management team at the helm, a proven, well-executed business model, plus market-leading positions in high-margin, niche products… our analysts believe there’s still plenty more potential growth in the pipeline.

Here’s your chance to discover exactly what has got our Motley Fool UK investment team all hot-under-the-collar about this tiny £350+ million enterprise… inside a specially prepared free investment report.

But here’s the really exciting part… right now, we believe many UK investors have quite simply never heard of this company before!

Click here to claim your copy of this special investment report — and we’ll tell you the name of this Top Small-Cap Stock… free of charge!

TomRodgers has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

The renowned analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply enter your email address below to discover how you can take advantage of this.

I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.